QSHC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
[Advanced]

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Underwood, P
Right arrow Articles by Beck, P
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Underwood, P
Right arrow Articles by Beck, P
Qual Saf Health Care 2002;11:230-232
© 2002 Quality and Safety in Health Care


ORIGINAL ARTICLE

Secondary prevention following myocardial infarction: evidence from an audit in South Wales that the National Service Framework for coronary heart disease does not address all the issues

P Underwood, P Beck

Llandough Hospital, Penlan Road, Llandough, Cardiff CF64 2XX, UK

Correspondence to:
Dr P Beck, Llandough Hospital, Penlan Road, Llandough, Cardiff CF64 2XX, UK;
paul{at}penarthhaven.freeserve.co.uk Objectives: To assess local uptake of treatments for secondary prevention of myocardial infarction and compare with targets in the National Service Framework (NSF) for coronary heart disease.

Design: Retrospective audit of case notes with follow up questionnaire at 1 year.

Setting: Teaching hospital and community.

Participants: 100 patients alive in December 1998 who had been admitted with an acute myocardial infarction between October 1997 and October 1998.

Main outcome measures: Local use of aspirin, ß blockers, ACE inhibitors, and statins.

Results: Unless contraindicated, discharge aspirin use was 100%, ß blocker use 84%, statin prescription and/or provision of dietetic advice 66%, and ACE inhibitors where any heart failure was found was 97%. 1–2 years later total cholesterol remained greater than 5.0 mmol/l in 25% of patients, 24% had stopped ß blockers, and ACE inhibitors remained at a low dose in half of those surveyed.

Conclusions: The NSF for coronary heart disease states that by April 2002 80–90% of patients should be prescribed appropriate secondary prevention. This had nearly been achieved at hospital discharge in 1999. However, follow up indicated problems in ongoing care with cholesterol targets not always being achieved, ß blockers often being stopped, and ACE inhibitors frequently remaining at low doses. Gaining maximum benefit from treatment depends on these secondary targets also being achieved. In these aspects of secondary prevention the NSF represents only an initial step towards effective prevention of coronary heart disease; perhaps the most difficult and expensive steps are yet to be fully realised.


Keywords: Secondary prevention; myocardial infarction; coronary heart disease; National Service Framework




This article has been cited by other articles:


Home page
Qual Saf Health CareHome page
M A Smith, E D Cox, and J M Bartell
Overprescribing of lipid lowering agents.
Qual. Saf. Health Care, August 1, 2006; 15(4): 251 - 257.
[Abstract] [Full Text] [PDF]


Home page
HeartHome page
P M Underwood, L S Cozma, K Laji, H Cohen, K Oboubie, and P Beck
Secondary prevention of coronary heart disease in South Wales: a survey following myocardial infarction
Heart, November 1, 2004; 90(11): 1332 - 1333.
[Full Text] [PDF]


Home page
Qual Saf Health CareHome page
K Checkland and M Marshall
National Service Frameworks as tools for quality improvement
Qual. Saf. Health Care, September 1, 2002; 11(3): 211 - 212.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 2002 by the BMJ Publishing Group Ltd.